David Nakasone

Investor Relations Contact at TARSUS PHARMACEUTICALS, INC.

Health Technology

Consumer Services

Profile

David Nakasone is Senior Director-Investor Relations at Tarsus Pharmaceuticals, Inc. since 2021.
Formerly, Mr. Nakasone was Director-Investor Relations at Lineage Cell Therapeutics, Inc., Associate Director-Investor Relations at Ionis Pharmaceuticals, Inc., and Investor Relations Contact at Allergan, Inc. from 2013 to 2015.
Education includes undergraduate studies at San Diego State University.

David Nakasone active positions

Companies	Position	Start
TARSUS PHARMACEUTICALS, INC.	Investor Relations Contact	2021-08-31

All active positions of David Nakasone

Former positions of David Nakasone

Companies	Position	End
ALLERGAN, INC.	Public Communications Contact	2015-05-31
IONIS PHARMACEUTICALS, INC.	Public Communications Contact	-
LINEAGE CELL THERAPEUTICS, INC.	Investor Relations Contact	-

See the detail of David Nakasone's experience

Training of David Nakasone

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David Nakasone's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Allergan, Inc. Allergan, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products	Health Technology
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutic products for retinal & neurological diseases and disorders and oncology	Health Technology
Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs	Health Technology
San Diego State University San Diego State University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapeutic drugs for blepharitis	Health Technology